China Merchants' international research report indicates that multinational leaders acquiring China's domestic Innovative Drug companies highlights the Global pharmaceutical market's recognition of China's innovative strength. Traditional pharmaceutical companies have been continuously strengthening their R&D transformation and overseas business development cooperation in recent years, and the quality of cooperation has been steadily improving. Collaborations are gradually shifting from small and medium-sized biotech companies to large multinational pharmaceutical companies. Clinical pipelines are continually implementing the strategy of going global for both mid-to-late stage and early stage Assets.

China Merchants stated that in the domestic Innovative Drug industry, the top choices are Hansoh (03692.HK) and Rongchang (09995.HK). Among them, after Hansoh Pharmaceuticals' oral 'GLP-1' achieved its first international expansion, it is expected that the company will continue to realize more business development in the fields of dual antibodies or ADC; as for the US stock Innovative Drug industry, the top choice is Alnylam (ALNY.US), which is expected to further accelerate its revenue growth in fiscal year 2025.

~